Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor , is exhibiting promising outcomes in early clinical assessments . Current research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/